| Primary |
| Metastatic Pain |
90.5% |
| Therapeutic Procedure |
2.9% |
| Metastases To Bone |
2.0% |
| Bone Pain |
1.1% |
| Diagnostic Procedure |
1.1% |
| Metastasis |
0.9% |
| Drug Use For Unknown Indication |
0.6% |
| Breast Cancer |
0.3% |
| Photon Radiation Therapy To Bone |
0.3% |
| Product Used For Unknown Indication |
0.3% |
|
| Condition Aggravated |
12.3% |
| Anaemia |
11.4% |
| White Blood Cell Count Decreased |
9.5% |
| Platelet Count Decreased |
8.6% |
| No Adverse Event |
7.3% |
| Disease Progression |
6.8% |
| Death |
5.5% |
| Disseminated Intravascular Coagulation |
5.0% |
| Prostate Cancer |
4.1% |
| Vomiting |
3.6% |
| Interstitial Lung Disease |
3.2% |
| Pancytopenia |
3.2% |
| Pneumonia |
3.2% |
| Nausea |
2.7% |
| Prostate Cancer Metastatic |
2.7% |
| Pyrexia |
2.7% |
| Sepsis |
2.7% |
| Bone Pain |
1.8% |
| Lung Neoplasm Malignant |
1.8% |
| Malignant Neoplasm Progression |
1.8% |
|
| Secondary |
| Metastatic Pain |
48.8% |
| Therapeutic Procedure |
25.6% |
| Diagnostic Procedure |
11.6% |
| Invasive Ductal Breast Carcinoma |
9.3% |
| Hormone Therapy |
2.3% |
| Metastases To Bone |
2.3% |
|
| Interstitial Lung Disease |
17.4% |
| Anaemia |
13.0% |
| Disseminated Intravascular Coagulation |
8.7% |
| Myelodysplastic Syndrome |
8.7% |
| No Adverse Event |
8.7% |
| Pulmonary Oedema |
8.7% |
| Blood Sodium Decreased |
4.3% |
| Diarrhoea |
4.3% |
| Leukaemia |
4.3% |
| Multi-organ Failure |
4.3% |
| Pancytopenia |
4.3% |
| Platelet Count Decreased |
4.3% |
| Prostate Cancer |
4.3% |
| Second Primary Malignancy |
4.3% |
|
| Concomitant |
| Prostate Cancer |
28.6% |
| Metastases To Bone |
25.7% |
| Cancer Pain |
11.4% |
| Anaemia |
8.6% |
| Evan's Syndrome |
8.6% |
| Metastatic Pain |
5.7% |
| Bone Pain |
2.9% |
| Breast Cancer |
2.9% |
| Prophylaxis |
2.9% |
| Prostate Cancer Metastatic |
2.9% |
|
| Tooth Abscess |
37.5% |
| Paralysis |
12.5% |
| Pathological Fracture |
12.5% |
| Platelet Count Decreased |
12.5% |
| Prostate Cancer |
12.5% |
| Pubis Fracture |
12.5% |
|
